Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Emergence of Carbapenemase Genes in Gram-Negative Bacteria Isolated from the Wastewater Treatment Plant in A Coruña, Spain

  • Nasser-Ali, Mohammed
  • Aja-Macaya, Pablo
  • Conde-Pérez, Kelly
  • Trigo Tasende, Noelia
  • Rumbo-Feal, Soraya
  • Fernández González, Ana
  • Bou, Germán
  • Poza, Margarita
  • Vallejo, J. A.
[Abstract] Wastewater treatment plants (WWTPs) are recognized as important niches of antibiotic-resistant bacteria that can be easily spread to the environment. In this study, we collected wastewater samples from the WWTP of A Coruña (NW Spain) from April 2020 to February 2022 to evaluate the presence of Gram-negative bacteria harboring carbapenemase genes. Bacteria isolated from wastewater were classified and their antimicrobial profiles were determined. In total, 252 Gram-negative bacteria carrying various carbapenemase genes were described. Whole-genome sequencing was conducted on 55 selected carbapenemase producing isolates using Oxford Nanopore technology. This study revealed the presence of a significant population of bacteria carrying carbapenemase genes in WWTP, which constitutes a public health problem due to their risk of dissemination to the environment. This emphasizes the usefulness of WWTP monitoring for combating antibiotic resistance. Data revealed the presence of different types of sequences harboring carbapenemase genes, such as blaKPC-2, blaGES-5, blaGES-6, blaIMP-11, blaIMP-28, blaOXA-24, blaOXA-48, blaOXA-58, blaOXA-217, and blaVIM-2. Importantly, the presence of the blaKPC-2 gene in wastewater, several months before any clinical case was detected in University Hospital of A Coruña, suggests that wastewater-based epidemiology can be used as an early warning system for the surveillance of antibiotic-resistant bacteria., The present study received funding from the Instituto de Salud Carlos III (ISCIII), Spain, through the project PI20/00413, co-funded by the European Union (EU) to M.P. and by CIBER de Enfermedades Infecciosas: CIBERINFEC, ISCIII (CB21/13/00055) to G.B and M.P.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

The Multispecies Microbial Cluster of Fusobacterium, Parvimonas, Bacteroides and Faecalibacterium as a Precision Biomarker for Colorectal Cancer Diagnosis

  • Ladra, Susana
  • Poza, Margarita
  • Conde-Pérez, Kelly
  • Aja-Macaya, Pablo
  • Buetas, Elena
  • Trigo Tasende, Noelia
  • Nasser-Ali, Mohammed
  • Rumbo-Feal, Soraya
  • Nión, P.
  • Martin-De Arribas, E.
  • Estévez, Lara
  • Otero Alén, Begoña
  • Noguera, José
  • Concha López, Ángel
  • Pardiñas López, Simón
  • Carda-Diéguez, Miguel
  • Gómez-Randulfe, Igor
  • Martínez-Lago, Nieves
  • Antón-Aparicio, Luis M.
  • Bou, Germán
  • Mira, Alex
  • Vallejo, J. A.
[Abstract] The incidence of colorectal cancer (CRC) has increased worldwide, and early diagnosis is crucial to reduce mortality rates. Therefore, new noninvasive biomarkers for CRC are required. Recent studies have revealed an imbalance in the oral and gut microbiomes of patients with CRC, as well as impaired gut vascular barrier function. In the present study, the microbiomes of saliva, crevicular fluid, feces, and non-neoplastic and tumor intestinal tissue samples of 93 CRC patients and 30 healthy individuals without digestive disorders (non-CRC) were analyzed by 16S rRNA metabarcoding procedures. The data revealed that Parvimonas, Fusobacterium, and Bacteroides fragilis were significantly over-represented in stool samples of CRC patients, whereas Faecalibacterium and Blautia were significantly over-abundant in the non-CRC group. Moreover, the tumor samples were enriched in well-known periodontal anaerobes, including Fusobacterium, Parvimonas, Peptostreptococcus, Porphyromonas, and Prevotella. Co-occurrence patterns of these oral microorganisms were observed in the subgingival pocket and in the tumor tissues of CRC patients, where they also correlated with other gut microbes, such as Hungatella. This study provides new evidence that oral pathobionts, normally located in subgingival pockets, can migrate to the colon and probably aggregate with aerobic bacteria, forming synergistic consortia. Furthermore, we suggest that the group composed of Fusobacterium, Parvimonas, Bacteroides, and Faecalibacterium could be used to design an excellent noninvasive fecal test for the early diagnosis of CRC. The combination of these four genera would significantly improve the reliability of a discriminatory test with respect to others that use a single species as a unique CRC biomarker., The authors want to appreciate the good disposition of all the CRC patients for collaborating with us. We would like to thank Gema Carro Díaz and Montserrat Ingelmo Sánchez for their assistance during patients' recruitment time and also during tissue sample collection. This work would not be possible without the support of professionals from the Microbiology, Surgery, Pathology and Oncology Services and Biobank of CHUAC (Spain). The present study received funding from the Instituto de Salud Carlos III (ISCIII), Spain, through the project PI20/00413, cofunded by the European Union (EU) to MP. The whole work has been also supported by the project RTI2018-102032-B-I00 from the Spanish Ministry of Science and Innovation to AM and by CIBER INFEC ISCIII (CB21/13/00055) to GB and MP Biobank of A Coruña was supported by ISCIII-Fondos FEDER (EU) by grant PT20/00128. KC-P was financially supported by the Spanish Association against Cancer (AECC). EB was supported by a grant from the Spanish Ministry of Science and Innovation PRE2019-088126. SL and EM-DA were supported by grants from GAIN (Xunta de Galicia, Spain) with references ED431C 2021/53 and ED431G 2019/01., Xunta de Galicia; ED431C 2021/53, Xunta de Galicia; ED431G 2019/01
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Parvimonas Micra Can Translocate From the Subgingival Sulcus of the Human Oral Cavity to Colorectal Adenocarcinoma

  • Conde-Pérez, Kelly
  • Buetas, Elena
  • Aja-Macaya, Pablo
  • Martin-De Arribas, E.
  • Iglesias Corrás, Iago
  • Trigo Tasende, Noelia
  • Nasser-Ali, Mohammed
  • Estévez, Lara
  • Rumbo-Feal, Soraya
  • Otero Alén, Begoña
  • Noguera, José
  • Concha López, Ángel
  • Pardiñas López, Simón
  • Carda-Diéguez, Miguel
  • Gómez-Randulfe, Igor
  • Martínez-Lago, Nieves
  • Ladra, Susana
  • Antón-Aparicio, Luis M.
  • Bou, Germán
  • Mira, Alex
  • Vallejo, J. A.
  • Poza, Margarita
[Abstract] Oral and intestinal samples from a cohort of 93 colorectal cancer (CRC) patients and 30 healthy controls (non-CRC) were collected for microbiome analysis. Saliva (28 non-CRC and 94 CRC), feces (30 non-CRC and 97 CRC), subgingival fluid (20 CRC), and tumor tissue samples (20 CRC) were used for 16S metabarcoding and/or RNA sequencing (RNAseq) approaches. A differential analysis of the abundance, performed with the ANCOM-BC package, adjusting the P-values by the Holm-Bonferroni method, revealed that Parvimonas was significantly over-represented in feces from CRC patients (P-value < 0.001) compared to healthy controls. A total of 11 Parvimonas micra isolates were obtained from the oral cavity and adenocarcinoma of CRC patients. Genome analysis identified a pair of isolates from the same patient that shared 99.2% identity, demonstrating that P. micra can translocate from the subgingival cavity to the gut. The data suggest that P. micra could migrate in a synergistic consortium with other periodontal bacteria. Metatranscriptomics confirmed that oral bacteria were more active in tumor than in non-neoplastic tissues. We suggest that P. micra could be considered as a CRC biomarker detected in non-invasive samples such as feces., This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI20/00413 and co-funded by the European Union to MP. The work has been also supported by the project RTI2018-102032-B-I00 from the Spanish Ministry of Science and Innovation to AM and by the CIBER INF ISCIII (CB21/13/00055) to GB and MP. Biobank of University Hospital Complex of A Coruña was supported by Instituto de Salud Carlos III – Fondos FEDER (EU) by grant PT20/00128. K. Conde-Pérez was financially supported with a predoctoral fellowship by the Asociación Española Contra el Cáncer (AECC). E. Buetas is supported by a grant from the Spanish Ministry of Science and Innovation with the reference PRE2019-088126. S. Ladra, E. Martin-De Arribas and Iago Iglesias-Corrás are supported by grants from GAIN (Xunta de Galicia, Spain) with references ED431C 2021/53 and ED431G, Xunta de Galicia; ED431C 2021/53, Xunta de Galicia; ED431G
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Epidemiology, resistance genomics and susceptibility of Acinetobacter species: results from the 2020 Spanish nationwide surveillance study

  • Lasarte-Monterrubio, Cristina
  • Guijarro, Paula
  • Alonso-García, Isaac
  • Outeda-García, Michelle
  • Maceiras, Romina
  • González-Pinto, Lucía
  • Martínez Guitián, Marta
  • Fernández-Lozano, Carlos
  • Vázquez-Ucha, Juan Carlos
  • Bou, Germán
  • Arca-Suárez, Jorge
  • Beceiro Casas, Alejandro
[Abstract]: Background: As increasing antibiotic resistance in Acinetobacter baumannii poses a global healthcare challenge, understanding its evolution is crucial for effective control strategies. Aim: We aimed to evaluate the epidemiology, antimicrobial susceptibility and main resistance mechanisms of Acinetobacter spp. in Spain in 2020, and to explore temporal trends of A. baumannii. Methods: We collected 199 single-patient Acinetobacter spp. clinical isolates in 2020 from 18 Spanish tertiary hospitals. Minimum inhibitory concentrations (MICs) for nine antimicrobials were determined. Short-read sequencing was performed for all isolates, and targeted long-read sequencing for A. baumannii. Resistance mechanisms, phylogenetics and clonality were assessed. Findings on resistance rates and infection types were compared with data from 2000 and 2010. Results: Cefiderocol and colistin exhibited the highest activity against A. baumannii, although colistin susceptibility has significantly declined over 2 decades. A. non-baumannii strains were highly susceptible to most tested antibiotics. Of the A. baumannii isolates, 47.5% (56/118) were multidrug-resistant (MDR). Phylogeny and clonal relationship analysis of A. baumannii revealed five prevalent international clones, notably IC2 (ST2, n = 52; ST745, n = 4) and IC1 (ST1, n = 14), and some episodes of clonal dissemination. Genes blaOXA-23, blaOXA-58 and blaOXA-24/40 were identified in 49 (41.5%), eight (6.8%) and one (0.8%) A. baumannii isolates, respectively. ISAba1 was found upstream of the gene (a blaOXA-51-like) in 10 isolates. Conclusions: The emergence of OXA-23-producing ST1 and ST2, the predominant MDR lineages, shows a pivotal shift in carbapenem-resistant A. baumannii (CRAB) epidemiology in Spain. Coupled with increased colistin resistance, these changes underscore notable alterations in regional antimicrobial resistance dynamics., This work was supported by Projects PI20/01212 and PI23/00851 awarded to AB, Project PI21/00704 awarded to GB, and Project PI22/01212 awarded to JA-S, funded by the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. The work was also supported by CIBER-Consorcio Centro de Investigación Biomédica en Red- de Enfermedades Infecciosas, Instituto de Salud Carlos III (CB21/13/00055), Ministerio de Ciencia e Innovación and Unión Europea—NextGenerationEU and by project IN607A 2020/05 (GAIN-Agencia Gallega de InnovaciónConsellería de Economía, Emprego e Industria) awarded to GB and project IN607D 2021/12 awarded to AB. JA-S was financially supported by the Juan Rodés program (ISCIII, JR21/00026), JCV-U was financially supported by IN606B-2022/009 (Xunta de Galicia), CL-M was financially supported by PI20/01212 (ISCIII), PG-S was financially supported by IN606A 2021/021 Grant (Xunta de Galicia). MO was financially supported by IN607D 2021/12. IA-G was financially supported by the Rio Hortega program (ISCIII, CM21/00076). MM-G was financially supported by RSU.UDC.M505 (Ministerio de Universidades)., Xunta de Galicia; IN607A 2020/05, Xunta de Galicia; IN607D 2021/12, Xunta de Galicia; IN606B-2022/009, Xunta de Galicia; IN606A 2021/021, Xunta de Galicia; IN607D 2021/12, Universidade da Coruña; RSU.UDC.M505
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Nanopore full length 16S rRNA gene sequencing increases species resolution in bacterial biomarker discovery

  • Aja-Macaya, Pablo
  • Conde-Pérez, Kelly
  • Noelia Trigo-Tasende
  • Nasser-Ali, Mohammed
  • Nión, P.
  • Rumbo-Feal, Soraya
  • Ladra, Susana
  • Bou, Germán
  • Vallejo, J. A.
  • Poza, Margarita
Raw sequence reads generated from 16S rRNA gene sequencing by MiSeq (Illumina-V3V4) and MinION (ONT-V1V9, Dorado sup v4.1.0) are available in the NCBI SRA database under bioproject PRJNA911189. Used scripts and additional documentation are available at https://github.com/Pablo-Aja-Macaya/CRC-ONT16S., [Abstract]: Discovery of disease-related bacterial biomarkers could be a useful approach for early prevention or diagnosis of various afflictions, such as colorectal cancer. This typically involves analyzing small regions of the 16S rRNA gene (e.g. V3V4) through short-read technologies like Illumina, obtaining genus-level results. However, recent developments in third-generation sequencing, such as Oxford Nanopore Technologies (ONT)’s new R10.4.1 chemistry and its improved basecalling models, are beginning to allow for a more complete and accessible species-level analysis through full-length 16S rRNA gene sequencing (spanning regions V1-V9). Thus, the goal of this study was to compare and evaluate both approaches, using colorectal cancer biomarker discovery as a representative case. This was achieved through the analysis of feces from 123 subjects, comparing both methods (Illumina-V3V4 with DADA2 and QIIME2 vs. ONT-V1V9 with Emu), multiple Dorado basecalling models (fast, hac and sup) and multiple databases (SILVA vs. Emu’s Default database). Basecalling models broadly resulted in similar taxonomic output, but had significantly higher observed species and different taxonomic identification the lower the basecalling quality (p-value<0.05). Database choice with Emu influenced the identified species greatly, with Emu’s Default database obtaining significantly higher diversity and identified species than SILVA (p-value<0.05). However, it overconfidently classified at times what should be an unknown species as the closest match due to its database structure. Bacterial abundance between Illumina-V3V4 and ONT-V1V9 at the genus level correlated well (R2 0.8). Nanopore sequencing identified more specific bacterial biomarkers for colorectal cancer than those obtained with Illumina, such as Parvimonas micra, Fusobacterium nucleatum, Peptostreptococcus stomatis, Peptostreptococcus anaerobius, Gemella morbillorum, Clostridium perfringens, Bacteroides fragilis and Sutterella wadsworthensis. Prediction of colorectal cancer through manual feature selection and machine learning resulted in an AUC of 0.87 with 14 species or 0.82 with just 4 species (P. micra, F. nucleatum, B. fragilis and Agathobaculum butyriciproducens). Full 16S rRNA V1V9 sequencing through Oxford Nanopore and its new R10.4.1 chemistry achieved accurate species-level bacterial identification, facilitating the discovery of more precise disease-related biomarkers and increasing the taxonomic fidelity of future microbiome analyses., This study has been funded by the Instituto de Salud Carlos III (ISCIII), through the projects PI20/00413 and PI23/00696, cofunded by the European Union (EU) to MP. Also, the work was funded by the project IN607A2024/09 from Xunta de Galicia (Spain) to GB. Additionally, it has been supported by the project RTI2018-102032-B-I00 from the Spanish Ministry of Science and Innovation to AM and by CIBER INFEC ISCIII (CB21/13/00055) to GB and MP. KC-P was financially supported by the Spanish Association against Cancer (AECC) from December 2019 to December 2023. Additionally, this work, integrated into the framework of PERTE for Vanguard Health, has been co-financed by the Spanish Ministry of Science, Innovation and Universities with funds from the European Union NextGenerationEU, from the Recovery, Transformation and Resilience Plan (PRTR-C17.I1) and from the Autonomous Community of Galicia within the framework of the Biotechnology Plan Applied to Health to SL., Xunta de Galicia; IN607A2024/09
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

CARB-ES-19 Multicenter Study of Carbapenemase-Producing Klebsiella pneumoniae and Escherichia coli From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3

  • Cañada-García, Javier E.
  • Moure García, Zaira
  • Sola-Campoy, Pedro J.
  • Delgado-Valverde, Mercedes
  • Cano, María E.
  • Gijón, Desirèe
  • González, Mónica
  • Gracia-Ahufinger, Irene
  • Larrosa, María Nieves|||0000-0001-8808-0233
  • Mulet, Xavier
  • Pitart, Cristina|||0000-0002-3083-7915
  • Rivera, Alba|||0000-0002-9709-6162
  • Bou, German|||0000-0001-8837-0062
  • Calvo, Jorge
  • Cantón, Rafael|||0000-0003-1675-3173
  • González-López, Juanjo|||0000-0003-2419-5909
  • Martínez-Martínez, Luis
  • Navarro Risueño, Ferran|||0000-0002-4302-2838
  • Oliver, Antonio|||0000-0001-9327-1894
  • Palacios-Baena, Zaira R.|||0000-0002-1713-6807
  • Pascual Hernández, Álvaro|||0000-0002-8672-5891
  • Ruiz-Carrascoso, Guillermo
  • Vila Estapé, Jordi|||0000-0002-8025-3926
  • Aracil, Belén
  • Pérez-Vázquez, María
  • Oteo-Iglesias, Jesús|||0000-0003-3327-8263
Objectives: CARB-ES-19 is a comprehensive, multicenter, nationwide study integrating whole-genome sequencing (WGS) in the surveillance of carbapenemase-producing K. pneumoniae (CP-Kpn) and E. coli (CP-Eco) to determine their incidence, geographical distribution, phylogeny, and resistance mechanisms in Spain. Methods: In total, 71 hospitals, representing all 50 Spanish provinces, collected the first 10 isolates per hospital (February to May 2019); CPE isolates were first identified according to EUCAST (meropenem MIC.